It is known that anti–PD-1/PD-L1 antibodies are not fully effective on NSCLC with EGFR mutation or ALK fusion19 and are often used for EGFR and ALK wild-type mutations. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.